China, IPOs

What other biotech news have you been missing? A big China IPO and more

After the Hong Kong exchange saw the first slate of biotech IPOs plunge well below their debut price, the investment crowd got more than a little worried about what the future held for other Chinese players looking to raise cash. But Shanghai Junshi Biosciences has helped ease the fretting — for now — after watching its stock leap on their rollout Monday.

According to Reuters the company raised close to $400 million and then cheered on a 22% surge in their stock price. And that follows a successful launch for Innovent, another premier China biotech, which has also seen a surge since their IPO some weeks ago.

Ascletis, the first to take the plunge, has seen 60% of its market cap disappear after the historic first step this year. And BeiGene has also experienced heavy turbulence.

Linus Yip, Chief Strategist at First Shanghai Securities, told Reuters that a more realistic valuation helped set the stage for the latest IPO to succeed.


Histogenics shares eviscerated after FDA frowns on PhIII data

Histogenics $HSGX saw its share price get shredded after reporting their decision to drop NeoCart after the FDA demanded to see more data on NeoCart before they would accept a BLA for review. The stock dropped 75% as the biotech added that it is bringing in consultants to review strategic options — which includes bankruptcy protection. Histogenics shares are now deep in penny stock territory.


AbbVie pays India biotech $30M to partner on MALT1 for cancer

AbbVie has turned to India’s Lupin for an add-on approach for its oncology R&D group. 

Lupin says that the pharma giant is paying $30 million in cash upfront to partner on its MALT1 inhibitors. The protein is linked with T-cell and B-cell lymphocyte activation, and AbbVie plans to test it for hematological cancers.

If it works, there are $947 million in milestones to collect.


Microbiome startup Vedanta scores $27M in Series C 

Unlike rivals such as Seres and Rebiotix who are developing pills in an effort to treat disease by harnessing gut microbes found in healthy feces, Vedanta is developing a consortium of bacteria manufactured from pure, clonal cell banks that the biotech hopes can induce a range of immune responses.

The Cambridge, Massachusetts-based company, which has already joined forces with J&J’s $JNJ Janssen and Bristol-Myers Squibb $BMY, on Monday said it had raised $27 million in a Series C round from investors including the Bill & Melinda Gates Foundation, Bristol-Myers, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health.

The money will be used to finance the development of 4 of the company’s experimental drugs, including a Phase I/II study of VE416 in food allergy, a Phase Ib/II study of VE800 and Bristol-Myer’s Opdivo in advanced or metastatic cancers, and the recently initiated Phase II study of VE303 in recurrent C. diff, which were created out of Vedanta’s cluster of bacterial strains.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->